Concomitant HPV vaccination and HPV screening for rapid elimination of HPV infection and cervical cancer in Sweden

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518857-41-00

Enrollment

150000

Registered

2024-11-29

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPV infection and related diseases, such as cervical intraepithelial neoplasia grade 2 and 3 and cervical cancer.

Brief summary

Uptake of HPV vaccine in eligible women, by county and age strata.

Detailed description

Compliance with HPV vaccine administration Schedule.

Interventions

DRUGGardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant

DRUGadsorbed)

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Uptake of HPV vaccine in eligible women, by county and age strata.	—

Secondary

Measure	Time frame
Compliance with HPV vaccine administration Schedule.	—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026